Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | PKM | P14618 | 1/20 | 0.33 |
| ▸ | HPGD | P15428 | 1/20 | 0.33 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.33 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.33 |
| ▸ | MC4R | P32245 | 1/20 | 0.33 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14197801 | 0.69 | SLC18A3 (0.37) | ALDH1A1HPGD | |
| SCHEMBL13955386 | 0.66 | CHRM5 (0.47) | — | |
| SCHEMBL17888277 | 0.63 | KEAP1 (0.54) | ALDH1A1MAPT | |
| SCHEMBL18739944 | 0.63 | MGLL (0.38) | ALDH1A1MAPTPKMHPGDALOX15 | |
| SCHEMBL17888250 | 0.62 | CHRM4 (0.35) | ALDH1A1PKM | |
| SCHEMBL23972258 | 0.61 | LMNA (0.32) | ALDH1A1MAPT | |
| SCHEMBL17888264 | 0.61 | KEAP1 (0.51) | ALDH1A1MAPT | |
| SCHEMBL23972320 | 0.60 | POLB (0.57) | ALDH1A1MAPTHSD17B10 | |
| SCHEMBL23972259 | 0.60 | ALDH1A1 (0.38) | ALDH1A1MAPT | |
| SCHEMBL91421 | 0.60 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4183415-A1 | TRPV4 INHIBITOR AS THERAPEUTIC DRUG FOR EYE DISEASE | RaQualia Pharma Inc. (JP) | 2023-05-24 | — | — | EP | disclosed |
| WO-2021221169-A1 | PYRIMIDIN-4(3H)-ONE DERIVATIVES AS TRPV4 ANTAGONISTS | RAQUALIA PHARMA INC. (JP) | 2021-11-04 | — | — | WO | disclosed |